

1.	<p>Treatment & Condition</p> <p>Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban</p>
2.	<p>Associated appraisal body & Summary of ruling</p> <p>NICE Technology appraisal guidance [TA697] Published: 12 May 2021 https://www.nice.org.uk/guidance/TA697</p> <ul style="list-style-type: none"> • Andexanet alfa is recommended as an option for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding, only if: <ul style="list-style-type: none"> ○ the bleed is in the gastrointestinal tract, and ○ the company provides andexanet alfa according to the commercial arrangement. • Andexanet alfa is recommended only in research for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding in the skull (intracranial haemorrhage; ICH), in the form of an ongoing randomised trial mandated by the regulator.
3.	<p>Number of people in Northern Ireland expected to take up service/therapy</p> <p>Using the NICE Resource Impact Template that accompanies NICE TA697, it is estimated that by year 5 the number of people in NI eligible for treatment with andexanet alfa for this indication in-line with NICE TA697 will be:</p> <ul style="list-style-type: none"> • 41 people treated with low-dose andexanet alfa • 8 people treated with high-dose andexanet alfa
4.	<p>Patient Access Scheme Availability (Yes/No)</p> <p>The company has a commercial arrangement. This makes andexanet alfa available to the NHS with a discount. The size of the discount is commercial in confidence.</p>
5.	<p>Infrastructure Requirements</p> <p>Any additional infrastructure costs associated will be dealt with as part of the routine commissioning process.</p>
6.	<p>Expected implementation period</p> <p>There is no impediment to immediate implementation for new patients.</p>
7.	<p>Commissioning arrangements</p> <p>Andexanet alfa for this indication is commissioned by HSCB. Providers are HSC</p>

	hospital trusts, and primary care.
8.	Monitoring arrangements Through usual monitoring of primary care drug budgets.
9.	DoH (NI) Legislative/Policy Caveats This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case. The Rural Needs Act NI 2016 has been considered and this guidance, which is purely of a technical nature, is not regarded as falling within the scope of the act.